Study defines changes in phosphorylated alpha-synuclein in Parkinson’s disease, suggesting biomarker potential.
To define changes in cutaneous P-SYN quantification over 18 months in patients with Parkinson’s disease (PD) and idiopathic REM sleep behavior disorder (iRBD).
No takes yet. Share an insight, caveat, or question.
Gibbons et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: